News

Monday March 29, 2021

Destiny Pharma to Join Equity Development Webinar

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel Primary endpoint achieved with >99% […]

Monday March 29, 2021

29 Mar 2021 – Destiny Pharma Phase 2b results – Analyst and Investor webcast and con...

The link to join the Phase 2b results webcast and conference call for analysts and investors, Monday 29th March at 1100 BST, is given below:- Phase 2b results webcast and […]

Monday March 29, 2021

Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001) Excellent […]

Tuesday March 16, 2021

16 Mar 2021 – Notice of Full Year Results and Clinical Trial Update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Clinical Trial Update Brighton, United Kingdom – 16th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage […]

Monday March 15, 2021

15 Mar 2021 – Destiny Pharma Announces Agreement with NIAID

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection Brighton, United Kingdom, 15 March 2021 […]

Wednesday March 10, 2021

10 Mar 2021 – Destiny Pharma CSO Joins UKRI COVID-19 Taskforce

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Chief Scientific Officer Dr Bill Love Joins UKRI COVID-19 Research and Innovation Taskforce Brighton, United Kingdom – 10th March […]